Epstein-Barr virus and lymphoproliferative disease

Current Opinion in Hematology

Volumn 6, Issue 1, 1999, Pages 25-29

  Mosier, Donald E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; EPSTEIN BARR VIRUS; HERPES VIRUS; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTE TRANSFORMATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; XENOTRANSPLANTATION;

COMBINED MODALITY THERAPY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032952664     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199901000-00005     Document Type: Review

References (59)

1. 1 Okano M: Epstein-Barr virus infection and its role in the expanding spectrum of human diseases. Acta Paediatr 1998, 87:11-18.
2. 2 Ishihara S, Okada S, Wakiguchi H, Kurashige T, Hirai K, Kawa-Ha K: Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. Am J Hematol 1997, 54:276-281.
3. 3 Jenson H, Leach C, McClain K, Joshi V, Pollock B, Parmley R, et al: Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. Leuk Lymphoma 1997, 27:303-314.
4. 4 Kaan P, Hegele R, Hayashi S, Hogg J: Expression of bcl-2 and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia. Thorax 1997, 52:12-16.
5. 5 Haque AK, Myers JL, Hudnall SD, Gelman BB, Lloyd RV, Payne D, Borucki M: Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: lesions with Epstein-Barr virus infection. Mod Pathol 1998, 11:347-356.
6. 6 Raab-Traub N, Webster-Cyriaque J: Epstein-Barr virus infection and expression in oral lesions. Oral Dis 1997, 3(suppl 1):S164-S170.
7. 7 Mozzanica N, Cattaneo A, Fracchiolla N, Boneschi V, Berti E, Gronda E, et al: Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression. J Heart Lung Transplant 1997, 16:964-968.
8. 8 Cho KH, Kim CW, Kwon OS, Yang SG, Park KG, Park MH, et al: Epstein-Barr virus-associated lymphoproliferative eruption with progression to large granular lymphocytic leukaemia. Br J Dermatol 1997, 137:426-430.
9. 9 Iwatsuki K, Ohtsuka M, Harada H, Han G, Kaneko F: Clinicopathologic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol 1997, 133:1081-1086.
10. 10 Abruzzo LV, Griffith LM, Nandedkar M, Aguilera NS, Taubenberger JK, Raffeld M, et al: Histologically discordant lymphomas with B-cell and T-cell components. Am J Clin Pathol 1997, 108:316-323.
11. 11 Yasunaga C, Kasai T, Nishihara G, Matsuo K, Takeda K, Urabe M, et al: Early development of Epstein-Barr virus-associated T-cell lymphoma after a living-related renal transplantation. Transplantation 1998, 65:1642-1644.
12. 12 Dockrell DH, Strickler JG, Paya CV: Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients. Clin Infect Dis 1998, 26:180-182.
13. 13 Nelson BP, Locker J, Nalesnik MA, Fung JJ, Swerdlow SH: Clonal and morphological variation in a posttransplant lymphoproliferative disorder: evolution from clonal T-cell to clonal B-cell predominance. Hum Pathol 1998, 29:416-421.
14. 14 Kanegane H, Hachie A, Miyawaki T, Tosato G: EBV-NK cells interactions and lymphoproliferative disorders. Leuk Lymphoma 1998, 29:491-498.
15. 15 Kanegane H, Bhatia K, Gutierrez M, Kaneda H, Wada T, Yachie A, et al: A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood 1998, 91:2085-2091.
16. 16 Hsi ED, Picken MM, Alkan S: Post-transplantation lymphoproliferative disorder of the NK-cell type: a case report and review of the literature. Mod Pathol 1998, 11:479-484.
17. 17 Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, et al: Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990, 64:2309-2318.
18. 18 Yalamanchili R, Harada S, Kieff E: The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation. J Virol 1996, 70:2468-2473.
19. 19 Izumi KM, Kaye KM, Kieff ED: The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A 1997, 94:1447-1452.
20. 20 Izumi KM, Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci U S A 1997, 94:12592-12597. This article, in conjunction with Izumi et al. [19], demonstrated a second site in the cytoplasmic C-terminal domain of LMP1 essential for B-cell transformation. Mutation of this site abolished transforming activity and wild-type LMP1 but not mutated LMP1 associated with the tumor necrosis factor receptor-associated death domain protein (TRADD) in a yeast two-hybrid screen. Transfected TRADD and the second LMP1 transformation site efficiently activated NF-κB.
21. 21 Kilger E, Kieser A, Baumann M, Hammerschmidt W: Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998, 17:1700-1709.
22. 22 Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998, 14:1413-1421. This article provides direct confirmation that the association of LMP1 with TRAF proteins is occurring in LPD. Double-immunofluorescence microscopy showed that LMP1 localized with and immunoprecipitated with TRAF-1 and TRAF-3 in eight of eight LPD samples. The in vitro studies by Izumi et al. [19,20] are thus directly relevant to the pathogenesis of LPD in patients.
23. 23 Eliopoulos AG, Rickinson AB: Epstein-Barr virus: LMP1 masquerades as an active receptor. Curr Biol 1998, 8:R196-R198.
24. 24 Hayashi K, Chen WG, Chen YY, Bacchi MM, Bacchi CE, Alvarenga M, et al: Deletion of Epstein-Barr virus latent membrane protein 1 gene in United States and Brazilian Hodgkin's disease and reactive lymphoid tissue: high frequency of a 30-bp deletion. Hum Pathol 1997, 28:1408-1414.
25. 25 Berger C, McQuain C, Sullivan JL, Nadel D, Quesenberry PJ, Knecht H: The 30-bp deletion variant of Epstein-Barr virus-encoded latent membrane protein-1 prevails in acute infectious mononucleosis. J Infect Dis 1997, 176:1370-1373. This study reports that the 30-bp LMP1 deletion variant was present in an unexpectedly high number of children (66%) with acute infectious mononucleosis or tonsillar hyperplasia, suggesting that this variant has a selective advantage in primary infection as well as in LPD.
26. 26 Kershaw GR, Berger C, McQuain C, al-Homsi AS, Pihan G, Quesenberry PJ, et al: Selective outgrowth of a posttransplant B-immunoblastic lymphoma expressing a latent membrane protein-1 deletion variant. Transplantation 1997, 64:1079-1081.
27. 27 Rothenberger S, Bachmann E, Knecht H: Molecular and functional analysis of the Epstein-Barr virus LMP1 oncogene promoter in lymphoproliferative diseases. Exp Hematol 1997, 25:1326-1332.
28. 28 Mehl AM, Fischer N, Rowe M, Hartmann F, Daus H, Trumper L, et al: Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma. Int J Cancer 1998, 76:194-200.
29. 29 Johnson RJ, Stack M, Hazlewood SA, Jones M, Blackmore CG, Hu LF, Rowe M: The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. J Virol 1998, 72:4038-4048. This article takes the dissenting view on the importance of the 30-bp deletion variant of LMP1 and shows that two naturally occurring 30-bp deletion variants are still able to upregulate NF-κB in human B-cell lines. One variant was deficient in upregulation of CD40 and CD54, but the other was not. The conclusion is that LMP1 may be important for transformation, but other parts of the EBV genome influence its activity.
30. 30 Scheinfeld AG, Nador RG, Cesarman E, Chadburn A, Knowles DM: Epstein-Barr virus latent membrane protein-1 oncogene deletion in posttransplantation lymphoproliferative disorders. Am J Pathol 1997, 151:805-812. This is a second dissenting article on the 30-bp LMP1 deletion. It finds the deletion variant of LMP1 in 44% of 58 posttransplant LPD lesions. The variant was identified in 36% of plasmacytic hyperplasia (see Table 1), 38% of polymorphic LPD, and 71% of malignant lymphomas and multiple myelomas. Although it is clear that the 30-bp deletion variant is not essential for LPD, it is still present at higher than expected frequency.
31. 31 Gutierrez MI, Spangler G, Kingma D, Raffeld M, Guerrero I, Misad O, et al: Epstein-Barr virus in nasal lymphomas contains multiple ongoing mutations in the EBNA-1 gene. Blood 1998, 92:600-606.
32. 32 Martin A, Flaman JM, Frebourg T, Davi F, el Mansouri S, Amouroux J, Raphael M: Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoproliferations. Br J Haematol 1998, 101:311-317.
33. 33 Yao QY, Croom-Carter DS, Tierney RJ, Habeshaw G, Wilde JT, Hill FG, et al: Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort. J Virol 1998, 72:4352-4363.
34. 34 Walling D, Edmiston S, Sixbey J, Abdel-Hamid M, Resnick L, Raab-Traub N: Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc Natl Acad Sci U S A 1992, 89:6560-6564.
35. 35 Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995, 85:552-565.
36. 36 Chadburn A, Chen JM, Hsu DT, Frizzera G, Cesarman E, Garrett TJ, et al: The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998, 82:1978-1987. This important article, which is summarized in Table 1, shows that the morphology and clonality (of both EBV and immunoglobulin gene rearrangements) is a strong predictor of clinical outcome in posttransplant LPD. The intermediate polymorphic lymphocytic/plasmacytic category appears to have the most variable outcome, and probably represents a spectrum of disease progression that is difficult to subdivide by currently available criteria.
37. 37 Rochford R, Mosier DE: Differential Epstein-Barr virus gene expression in B-cell subsets recovered from lymphomas in SCID mice after transplantation of human peripheral blood lymphocytes. J Virol 1995, 69:150-155.
38. 38 Brink AA, Dukers DF, van den Brule AJ, Oudejans JJ, Middledorp JM, Meijer CJ, Jiwa M: Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol 1997, 50:911-918.
39. 39 Randhawa PS, Pietrzak B, Nalesnik MA, Demetris AJ, Locker J: Subcutaneous implantation of human post-transplant lymphoproliferative disease lesions in SCID mice. Hematol Oncol 1997, 15:39-46.
40. 40 Perera SM, Thomas JA, Burke M, Crawford DH: Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J Pathol 1998, 184:177-184. This article shows that the T cells infiltrating LPD lesions are CD4 T cells, which are likely to enhance disease progression, rather than CD8 T cells, which should help control EBV infection. In conjunction with the study by Ngo et al. [42••], this makes it likely that EBV reactivation triggers chemokine production, which recruits cells important for the initiation of LPD.
41. 41 Callan M, Tan L, Annels N, Ogg G, Wilson J, O'Callaghan C, et al: Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998, 187:1395-1402. Although this article is only indirectly related to LPD, it is a striking demonstration with the new tetramer binding technology, which measures antigen-specific T-cell receptor expression of the high incidence (up to 44%) of EBV-specific cytotoxic T lymphocytes generated during primary EBV infection. These CD8 cytotoxic T lymphocytes were shown to persist at easily detectable levels for at least 3 years after infection. It is highly likely that these cells bear the responsibility for the lifelong control of EBV, and it is the loss of their activity that is the proximal precipitating event in LPD.
42. 42 Ngo VN, Lucy Tang H, Cyster JG: Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med 1998, 188:181-191. This article reports on the mouse homologue of a human chemokine induced by EBV infection, and shows that it is a potent mediator of naive T-cell-to-B-cell interaction in the T-cell zones of lymphoid tissue. EBV thus has evolved to be able to recruit cells that aid in its spread by providing new targets for infection.
43. 43 Pageaux GP, Bonnardet A, Picot MC, Perrigault PF, Coste V, Navarro F, et al: Prevalence of monoclonal immunoglobulins after liver transplantation: relationship with posttransplant lymphoproliferative disorders. Transplantation 1998, 65:397-400.
44. 44 Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, et al: Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997, 64:1438-1442.
45. 45 Hornef MW, Bein G, Wilhelm D, Fricke L, Kirchner H: ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation. Clin Diagn Lab Immunol 1997, 4:545-549.
46. 46 Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, et al: Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998, 91:3654-3661.
47. 47 Brandt CD, Sison AV, Rakusan TA, Saxena ES, Kaufman TE, O'Donnell RM, Sever JL: Epstein-Barr virus DNA in the blood of infants, young children, and adults by age and HIV status. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:69-72.
48. 48 Randhawa P, Whiteside T, Zeevi A, Nalesnik M, Alvares C, Gollin SM, et al: In-vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant lymphoproliferative disease: cytokine production and effect of interferon-alpha. In Vitro Cell Dev Biol Anim 1997, 33:803-808.
49. 49 Rochford R, Cannon MJ, Sabbe RE, Adusumilli K, Picchio G, Glynn JM, et al: Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines. Viral Immunol 1997, 10:183-195.
50. 50 Rochford R, Mosier DE: Immunobiology of Epstein-Barr virus-associated lymphomas. Clin Immunol Immunopathol 1994, 71:256-259.
51. 51 Carbone A, Gaidano G, Gloghini A, Larocca LM, Capello D, Canzonieri V, et al: Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998, 91:747-755.
52. 52 Rooney CM, Smith CA, Heslop HE: Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today 1997, 3:24-30.
53. 53 Orentas RJ, Lemas MV, Mullin MJ, Colombani PM, Schwarz K, Ambinder R: Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors. J Hematother 1998, 7:257-261.
54. 54 Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, et al: Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997, 64:848-852.
55. 55 Nadal D, Guzman J, Frohlich S, Braun DG: Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation. Exp Hematol 1997, 25:223-231.
56. 56 Kenney S, Ge JQ, Westphal EM, Olsen J: Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: Comparison of two different Epstein-Barr virus-based vectors. Hum Gene Ther 1998, 9:1131-1141. This article presents an interesting strategy to target potentially therapeutic or lethal EBV vectors to EBV-infected cells, which takes advantage of the unique replicative strategies employed by EBV.
57. 57 Hirai H, Satoh E, Osawa M, Inaba T, Shimazaki C, Kinoshita S, et al: Use of EBV-based vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem Biophys Res Commun 1997, 241:112-118.
58. 58 Moghaddam A, Koch J, Annis B, Wang F: Infection of human B lymphocytes with lymphocryptoviruses related to Epstein-Barr virus. J Virol 1998, 72:3205-3212. EBV-like viruses from rhesus macaques or baboons were found to use human CD21 for entry, and could infect EBV-transformed human B-cell lines but not normal B cells. This result suggests a postentry block to virus replication in human B cells, which is removed by coinfection with EBV, and means that EBV-like viruses in xenotransplants could be rescued by EBV reactivation.
59. 59 Hale G, Waldmann H: Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998, 91:3079-3083.